Patent Grant
10004796
The present invention relates in general to the field of immunization, and particularly, an adenoviral vector-based vaccine against enterovirus infection.
Enteroviruses, within the Picornaviridae family, are a genus of small, non-enveloped viruses containing positive-strand RNAs. The Enterovirus genus now comprises 12 species: Enterovirus A, Enterovirus B, Enterovirus C, Enterovirus D, Enterovirus E, Enterovirus F, Enterovirus G, Enterovirus H, Enterovirus J, Rhinovirus A, Rhinovirus B and Rhinovirus C. These viruses infect the intestinal tract but can cause various types of diseases. Typical enterovirus diseases are meningitis, paralysis, myocarditis, hand, foot and mouth-disease (HFMD), herpangina, pleurodynia, hepatitis, rash and respiratory diseases including pneumonia. The only enterovirus vaccine for use in human beings is vaccine of poliovirus which belongs to Enterovirus C. Currently, vaccines against non-polio enteroviruses are not available for human use.
Among Enterovirus A, enterovirus 71 (EV71) and coxsackievirus A group (CVA) infections are the most common causative factors of hand, foot, and mouth disease (HFMD) and other neurological disorders. Severe neurological disorders, including encephalitis, acute flaccid paralysis, pulmonary edema (PE), and hemorrhaging, culminating in fatality, particularly in EV71-infected children under 5 years old, have been reported [1-5]. Because EV71 and CVA infections can potentially become a new threat to global public health [1, 6-11], effective antiviral drugs and prophylactic vaccines are urgently needed.
Enterovirus genome consists of a single open reading frame that encodes the P1, P2, and P3 poly-proteins. The P2 and P3 regions encode nonstructural proteins (e.g., 3CD) responsible for virus replication and virulence. During viral RNA translation, the 2A protein catalyzes its N-terminal cleavage in cis, thereby releasing the capsid proteins in the P1 region from the nascent nonstructural proteins in the P2 and P3 regions. 3CD is released from the P3 precursor by autocatalytic cleavage. A 3C′ cleavage site in the polyprotein resides between the 3C and 3D portion of 3CD to generate 2 products, 3C′ and 3D′. When the P1 precursor is encoded by the P1 region, it can be cleaved by the 3C′ protease into VP0, VP1, and VP3. These 3 proteins spontaneously assemble into an icosahedral procapsid and pack the RNA genome into the provirion that could be a non-infectious empty (E)-particle or infectious full (F)-particle [12,13].
Human scavenger receptor class B, member 2 (hSCARB2) and human P-selectin glycoprotein ligand 1 (PSGL-1) have been identified as the important cell receptors for EV71 infection [14,15]. Our group [16] and Fujii et al. [17] have successfully developed transgenic mice expressing the human hSCARB2 receptor. In this promising model, transgenic animals infected with clinical EV71 isolates of the B4 and B5 subgenotypes developed HFMD-like skin rashes, whereas those inoculated with EV71 C2 and C4 subgenotypes or CVA16 suffered severe limb paralysis and death. In addition, passive administration of the monoclonal anti-EV71 VP1 neutralizing antibody N3 [26] reduced EV71 B5 infection-induced symptoms and protected the transgenic mice against EV71 C2-induced severe limb paralysis and death.
In a previous study [13], we produced a formalin-inactivated EV71 strain E59 (FI-EV71) vaccine candidate formulated with alum adjuvant, and found that FI-EV71 displayed high efficacy in the hSCARB2-Tg mouse challenge model [16]. In a human phase I clinical trial [18], FI-EV71 was safe and could elicit strong neutralizing antibody responses against current circulating EV71 isolates, but failed to protect against CVA16 infections. On the other hand, DNA vaccine (100 μg/mouse) and recombinant protein vaccine (10 μg/mouse) based on VP1, the most potent antigen on the EV71 virus, induce poorer immune responses than the inactivated virus vaccines and fail to effectively protect the mice against virus infection [19].
Virus-like particles, or VLPs, mimic the external protein structure of a virus without including the genetic material (DNA or RNA) that is necessary for viral replication. Without genetic material, VLP vaccines are incapable of causing infections themselves while at the same time presenting viral antigens in the most authentic configuration possible. VLPs of EV71 produced by insect cells also had been proved its efficacy in mice [20], which describes that VLP proteins are expressed in insect cells and then resemble to form VLPs and after purification, the VLPs are introduced to mice for immunization, inducing immune responses against the viral challenge. However, the different post-modification (such as glycosylation) of VLPs proteins produced from non-human cells might induce the different immunogenicity from human. The highest purity demand of VLPs during the production is also an obstacle.
There is still a need to develop an effective vaccine against enterovirus infections.
The present invention relates to a novel adenoviral vector-based DNA vaccine for generating immunity against enterovirus infection. In one embodiment, the present invention provides a recombinant adenoviral vector which comprises an expression cassette encoding a P1 protein and a 3CD protease of an enterovirus. In another embodiment, the present invention provides a recombinant adenoviral vector which comprises an expression cassette encoding a 3C protease or a 3CD protease of an enterovirus. It is unexpectedly found that vaccination of the recombinant adenoviral vector as described induces enhanced protective immunity against enterovirus infection, especially cellular (T cell) immune responses. It is also found that vaccination of the recombinant adenoviral vector as described induces specific 3C cellular immune responses and thus provides broad cross-protection against different species of enteroviruses, including at least enterovirus 71 and coxsackievirus A, because the amino acid sequences of the 3C protease among the enteroviruses are highly conserved.
Therefore, in one aspect, the present invention provides a recombinant adenoviral vector for generating immunity against enterovirus infection comprising an expression cassette encoding a P1 protein and a 3CD protease of an enterovirus. The present invention also provides a recombinant adenoviral vector for generating immunity against enterovirus infection comprising an expression cassette encoding a 3C protease or a 3CD protease of an enterovirus.
In another aspect, the present invention provides a vaccine composition for generating immunity against enterovirus infection comprising an effective amount of the recombinant adenoviral vector as described herein.
In a further aspect, the present invention provides a method of inducing an immune response in a subject against enterovirus infection, comprising administering to the subject an effective amount of the recombinant adenoviral vector or the vaccine composition as described herein. Also provided is use of the recombinant adenoviral vector or the vaccine composition as described herein for manufacturing a medicament (e.g. a vaccine) for inducing an immune response in a subject against enterovirus infection.
In addition, it is found that virus-like particles are formed in a mammalian cell expression system using the recombinant adenoviral vector of the invention encoding P1 and 3CD proteins. Therefore, the present invention further provides a method for producing virus like particles of an enterovirus, comprising
The details of one or more embodiments of the invention are set forth in the description below. Other features or advantages of the present invention will be apparent from the following detailed description of several embodiments, and also from the appending claims.
The foregoing summary, as well as the following detailed description of the invention, will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, there are shown in the drawings embodiments which are presently preferred. It should be understood, however, that the invention is not limited to the precise arrangements and instrumentalities shown.
In the drawings:
Unless defined otherwise, all technical and scientific terms used herein have the same meanings as is commonly understood by one of skill in the art to which this invention belongs.
As used herein, the articles “a” and “an” refer to one or more than one (i.e., at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.
The term “polynucleotide” or “nucleic acid” refers to a polymer composed of nucleotide units. Polynucleotides include naturally occurring nucleic acids, such as deoxyribonucleic acid (“DNA”) and ribonucleic acid (“RNA”) as well as nucleic acid analogs including those which have non-naturally occurring nucleotides. Polynucleotides can be synthesized, for example, using an automated DNA synthesizer. It will be understood that when a nucleotide sequence is represented by a DNA sequence (i.e., A, T, G, C), this also includes an RNA sequence (i.e., A, U, G, C) in which “U” replaces “T.” The term “cDNA” refers to a DNA that is complementary or identical to an mRNA, in either single stranded or double stranded form.
The term “complementary” refers to the topological compatibility or matching together of interacting surfaces of two polynucleotides. Thus, the two molecules can be described as complementary, and furthermore the contact surface characteristics are complementary to each other. A first polynucleotide is complementary to a second polynucleotide if the nucleotide sequence of the first polynucleotide is identical to the nucleotide sequence of the polynucleotide binding partner of the second polynucleotide. Thus, the polynucleotide whose sequence 5′-TATAC-3′ is complementary to a polynucleotide whose sequence is 5′-GTATA-3′.”
The term “encoding” refers to the inherent property of specific sequences of nucleotides in a polynucleotide (e.g., a gene, a cDNA, or an mRNA) to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom. Therefore, the phrase “a gene encoding a protein” means that transcription and translation of mRNA produced by that gene can produce the protein in a cell or other biological system. It is understood by a skilled person that numerous different polynucleotides can encode the same polypeptide as a result of the degeneracy of the genetic code. It is also understood that skilled persons may, using routine techniques, make nucleotide substitutions that do not affect the polypeptide sequence encoded by the polynucleotides described there to reflect the codon usage of any particular host organism in which the polypeptides are to be expressed. Therefore, unless otherwise specified, a “nucleotide sequence encoding an amino acid sequence” includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. Nucleotide sequences that encode proteins and RNA may include introns.
The term “recombinant” nucleic acid refers to a polynucleotide or nucleic acid molecule having sequences that are not naturally joined together. A recombinant nucleic acid may be present in the form of a construct e.g. a vector. “Vectors” may contain a given nucleotide sequence of interest and a regulatory sequence. Vectors may be used for expressing the given nucleotide sequence or maintaining the given nucleotide sequence for replicating it, manipulating it or transferring it between different locations (e.g., between different organisms). Vectors can be introduced into a suitable host cell for the above mentioned purposes.
As used herein, the term “operably linked” may mean that a polynucleotide is linked to an expression control sequence in such a manner to enable expression of the polynucleotide when a proper molecule (such as a transcriptional factor) is bound to the expression control sequence.
As used herein, the term “expression control sequence” or “regulatory sequence” means a DNA sequence that regulates expression of the nucleic acid sequence operably linked thereto in a certain host cell.
As used herein, the term “expression cassette” refers to a defined segment of a nucleic acid molecule that comprises the minimum elements needed for production of a transcriptional or translational product (RNA or protein) encoded by that nucleic acid molecule. For example, an expression cassette includes a polynucleotide sequence encoding a polypeptide to be expressed and sequences for controlling its expression such as a promoter and optionally an enhancer sequence, including any combination of cis-acting transcriptional control elements. For an adenoviral vector as described herein, an expression cassette can typically refer to that for expressing a heterologous gene product, rather than that for expressing adenoviral proteins encoded in the adenoviral genome.
Typically, in vectors, a given nucleotide sequence is operatively linked to a regulatory sequence, forming an expression cassette, such that when the vectors are introduced into a host cell, the given nucleotide sequence can be expressed in the host cell under the control of the regulatory sequence. The regulatory sequence may comprises, for example and without limitation, a promoter sequence (e.g., the cytomegalovirus (CMV) promoter, simian virus 40 (SV40) early promoter, T7 promoter, alcohol oxidase gene (AOX1) promoter, internal ribosome entry site (IRES) and elongation factor 1a promoter), a start codon, a replication origin, enhancers, an operator sequence, a secretion signal sequence (e.g., α-mating factor signal) and other control sequence (e.g., Shine-Dalgano sequences and termination sequences). Preferably, vectors may further contain a marker sequence (e.g., an antibiotic resistant marker sequence) for the subsequent screening procedure.
The term “vaccine” refers to an agent or composition containing an active component effective to induce protective immunity in a subject against a certain pathogen or disease. Traditionally, the active component of a vaccine is a polypeptide derived from a pathogen which is the target of the vaccine. The term “DNA vaccine” refers to a vaccine wherein the active component is composed of DNAs e.g. a DNA construct expressing a desired antigenic protein to induce protective immune responses. As described herein, a DNA vaccine can refer to a DNA construct for expressing viral proteins or VLPs of a virus and induce protective immune responses against the virus in a subject after vaccination.
A “subject” as used herein is a human or non-human mammal. Non-human mammals include, but are not limited to, primates, ungulates, canines and felines.
The term “adenovirus” as referred to herein indicates over 47 adenoviral subtypes isolated from humans, and as many from other mammals and birds. See, Strauss, “Adenovirus infections in humans,” in The Adenoviruses, Ginsberg, ed., Plenum Press, New York, N.Y., pp. 451 596 (1984).
The term “adenoviral vector” as used herein refers to an adenovirus in which the adenoviral genome has been manipulated to carry a nucleic acid sequence that is non-native with respect to the adenoviral genome. Therefore, a “recombinant adenoviral vector” as used herein typically comprises an adenoviral genome and an expression cassette in which at least one exogenous nucleic acid sequence encoding a desired protein (e.g. P1 protein or 3CD protein or both) is included.
An adenoviral vector preferably contains at least a portion of each terminal repeat required to support the replication of the viral DNA, preferably at least about 90% of the full inverted terminal repeat (ITR) sequence, and the DNA required to encapsidate the genome into a viral capsid. Adenovirus from various origins can be used as the source of the viral genome for the adenoviral vector. A human adenovirus is preferred, for example, subgroup A (e.g., serotypes 12, 18 and 31), subgroup B (e.g., serotypes 3, 7, 11, 14, etc.), subgroup C (e.g., serotypes 1, 2, 5, and 6), subgroup D (e.g., serotypes 8, 9, 10, 13, 15, 17, 19, 20, etc.), subgroup E (e.g., serotype 4), subgroup F (e.g., serotypes 40 and 41) and others. Preferably, the adenoviral vector is of human subgroup C, especially serotype 2 or even more desirably serotype 5.
The adenoviral vector can be replication competent. Typically, the adenoviral vector is replication-deficient in host cells. The term “replication-defective” means that the adenoviral vector has a deficiency in one or more gene functions or regions of the adenoviral genome for replication (e.g. E1, E3 or E4 region) such that the vector keeps some low-level replication or does not replicate in normal host cells, especially those in a human to be infected by the adenoviral vector. The replication-defective adenoviral vector ensures the safety of the vaccine. In one embodiment, the adenoviral vector is deficient in E1 or E3 or both. A deficiency in a gene is defined as a mutation or deletion to completely remove or impair the function of the gene, for example, such that the function of the gene product is reduced by at least about 2-fold, 5-fold, 10-fold, 20-fold or more as compared to a native gene. The resulting replication-defective adenoviral vector can accommodate one or more exogenous nucleic acid sequences, in a proper site in the adenoviral genome, for expression of one or more desired proteins, while maintaining the ability to be packaged into adenoviral capsids. For the purpose of producing high titers of viral vector for stock, the replication-defective adenoviral vector is typically produced in complementing cell lines, such as 293 cells, which provide gene functions not present in the replication-defective adenoviral vector.
In one aspect, the present invention provides a recombinant adenoviral vector as a broad spectrum DNA vaccine for generating immunity against various enterovirus infections.
In one embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a P1 protein and a 3CD protease of an enterovirus. The recombinant adenoviral vector of the invention, Ad-P1-3CD, upon transfection in host cells, not only expresses adenoviral structure proteins but also enterovirus capsid proteins, and in addition to the adenovirus particles, VLPs formed by assembly of these expressed enterovirus capsid proteins, are produced, as demonstrated in western blotting and transmission electron microscopy. Ad-P1-3CD can be used as a broad spectrum DNA vaccine for generating immunity against various enterovirus infections, especially Enterovirus A covering EV71 and CVA. As shown in examples below, in animals, immunization of Ad-P1-3CD can induce neutralizing antibodies against EV71 and specific cellular CD44+ and CD8+ cellular immunities against both EV71 and CVA; and Ad-P1-3CD provides protection against EV71 and CVA infection in animals (100% survival of mice immunized with Ad-P1-3CD after challenge with EV71 or CVA, as compared with 0% survival of mice received saline or control adenoviral vector).
To construct the recombinant adenoviral vector of the invention, the exogenous DNA can be inserted in a proper site in the adenoviral genome of the vector using standard molecular biology and cell culture techniques, such as those described in Sambrook et al., Molecular Cloning, a Laboratory Manual, 3rd edition, Cold Spring Harbor Press, Cold Spring harbor, N.Y. (2001). When the adenoviral vector comprise two or more exogenous nucleic acid sequences for expressing proteins, the multiple nucleic acid sequences can be operably linked to different or the same promoters e.g. two nucleic acid sequences are each operably linked to the same one promoter, or each of the two nucleic acid sequences is operably linked to a different promoter. In this regard, the promoter can be a viral promoter such as a T7 promoter, a CMV promoter, a human immunodeficiency virus (HIV) long terminal repeat promoter, an internal ribosome entry site (IRES), a herpes thymidine kinase promoter or an adeno-associated viral promoter such as the p5 promoter and the like. Alternatively, the promoter can be a cellular promoter i.e. a promoter that is present in eukaryotic cells (animal cells or yeast cells), such as a ubiquitin promoter, a EF-1α promoter, a heat shock protein promoter, a β-active promoter, or an alcohol oxidase gene (AOX1) promoter.
In one certain embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette including a first nucleic acid fragment encoding the P1 protein and a second nucleic acid fragment encoding the 3CD protease. Specifically, the first nucleic acid fragment is operably linked to a first promoter for controlling expression of the P1 protein and the second nucleic acid fragment is operably linked to a second promoter for controlling expression of the 3CD protease, in which the first promoter and the second promoter are the same or different. Specific examples of the expression cassette in the recombinant adenoviral vector of the invention are as shown in
As used herein, a “P1 protein” is a protein product expressed by a P1 gene of an enterovirus. The amino acid sequence of the P1 protein and its corresponding nucleic acid are available in the art. In certain embodiments, the P1 protein as described herein is the one originated from EV71, particularly having the amino acid sequence of SEQ ID NO: 1, or the one from other enterovirus species having the amino acid sequence with at least 85%, 90% or 95% identity to SEQ ID NO: 1.
As used herein, a “3CD protease” is a protein product expressed by a 3CD gene of an enterovirus. The amino acid sequence of the 3CD protein and its corresponding nucleic acid are available in the art. In certain embodiments, the 3CD protein as described herein is the one originated from EV71, particularly having the amino acid sequence of SEQ ID NO: 2, or the one from other enterovirus species having the amino acid sequence with at least 85%, 90% or 95% identity to SEQ ID NO: 2.
In particular embodiments, the P1 protein and the 3CD protease are originated from the same species of an enterovirus, for example, EV71.
In certain examples, the recombinant adenoviral vector of the invention comprises an expression cassette which includes the nucleic acid sequence of SEQ ID NO: 3 (CMV-P1-IRES-3CD) or SEQ ID NO: 4 (CMV-P1-EF-1α-3CD).
In the present invention, it is also disclosed that a 3C specific cellular immunity is sufficient to protect various enterovirus infections, at least Enterovirus A infections, covering EV71 and CVA infections. Therefore, the present invention also provides a recombinant adenoviral vector for generating immunity against enterovirus infection comprising an expression cassette encoding a 3C protease or a 3CD protease of an enterovirus. In one embodiment, the present invention provides a recombinant adenoviral vector comprising an expression cassette carrying an exogenous DNA encoding a 3C protease of an enterovirus. In another embodiment, the present invention provides a recombinant adenoviral vector comprising an expression cassette carrying an exogenous DNA encoding a 3CD protease of an enterovirus. In a particular example, the 3C protease or the 3CD protease is originated from EV71.
As used herein, a “3C” protein is a protein product expressed by a 3C gene of an enterovirus. The amino acid sequence of the 3C protein and its corresponding nucleic acid are available in the art. In certain embodiments, the 3C protein as described herein is the one originated from EV71, particularly having the amino acid sequence of SEQ ID NO: 5, or the one from other enterovirus species having the amino acid sequence with at least 85%, 90% or 95% identity to SEQ ID NO: 5.
To determine the percent identity of two amino acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid sequence for optimal alignment with a second amino acid sequence). In calculating percent identity, typically exact matches are counted. The determination of percent homology or identity between two sequences can be accomplished using a mathematical algorithm known in the art, such as BLAST and Gapped BLAST programs, the NBLAST and XBLAST programs, or the ALIGN program.
An effective amount of the recombinant adenoviral vector of the invention as the active ingredient can be formulated with a pharmaceutically acceptable carrier into a composition of an appropriate form for the purpose of delivery or absorption or to enhance stability of the composition.
As used herein, “pharmaceutically acceptable” means that the carrier is compatible with the active ingredient in the composition, and preferably can stabilize said active ingredient and is safe to the individual receiving the treatment. Said carrier may be a diluent, vehicle, excipient, or matrix to the active ingredient. Viral vectors may be formulated as solutions or lyophilized powders for parenteral administration. Powders may be reconstituted with a suitable diluents or other pharmaceutically acceptable carrier before use. Suitable diluents for example are normal isotonic saline solution, standard 5% dextrose in water, or buffered sodium or ammonium acetate solution. Viral vectors may be prepared for oral administration. Some examples of appropriate solid carriers include lactose, dextrose, sucrose, sorbose, mannose, starch, Arabic gum, calcium phosphate, alginates, tragacanth gum, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, sterilized water, syrup, and methylcellulose. The composition may additionally comprise lubricants, such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preservatives, such as methyl and propyl hydroxybenzoates; sweeteners; and flavoring agents. The composition of the present invention can provide the effect of rapid, continued, or delayed release of the active ingredient after administration to a subject.
The composition of the present invention comprising the recombinant adenoviral vector of the invention, as a vaccine composition, can further formulated to comprise an adjuvant. Typical examples of adjuvants to enhance effectiveness of a vaccine composition include, but are not limited to, aluminum salts, oil-in-water emulsion formulations, saponin adjuvants, complete Freund's adjuvant (CFA) and incomplete Freund's adjuvant (IFA).
The present invention further provides a method of inducing an immune response in a subject against enterovirus infection, comprising administering to the subject an effective amount of the recombinant adenoviral vector or a vaccine composition thereof as disclosed herein. Also provided is use of the recombinant adenoviral vector or the vaccine composition as described herein for manufacturing a medicament (e.g. a vaccine) for inducing an immune response in a subject against enterovirus infection.
The term “an effective amount” refers to a dose or amount sufficient to provide a desired therapeutic effect in a treated subject, for example, sufficient to generate or induce an immune response against a pathogen (e.g. enterovirus) or an antigen (e.g., 3C or 3CD protein of an enterovirus) in the recipient thereof. The therapeutically effective amount may change depending on various reasons, such as administration route and frequency, body weight and species of the individual receiving said pharmaceutical, and purpose of administration. Persons skilled in the art may determine the dosage in each case based on the disclosure herein, established methods, and their own experience. For example, in certain embodiments, the recombinant adenoviral vector of the invention is administered in a dose of 1×107 to 1×1012 plaque-forming unit (pfu), e.g. 1×107, 1×108, 1×109, 1×1010, 1×1011, or 1×1012 pfu.
The term “immune response” may include, but is not limited to, a humoral response and a cell mediated immune response e.g. CD4+ or CD8+ cell activation.
A viral vector can be administered via any physiologically acceptable route, such as orally, parenterally (e.g. intramuscularly, intravenously, subcutaneously, and intraperitoneally), nasally, rectally, transdermally or inhalationally. In some embodiments, the viral vector can be administered orally, subcutaneously or intraperitoneally. Immunization can be performed by repeated administration, typically including an initial administration followed by subsequent booster administrations.
It is found in the invention that a 3C specific cellular immunity is sufficient to protect various enterovirus infections. Accordingly, the method of the invention is effective to provide cross-protective immunity against different enterovirus species due to highly conservation of the amino acid sequences of the 3C protein among different species of enterovirus. In certain embodiments, the method of the invention is effective in inducing an immune response against Enterovirus A, covering both EV71 and CVA, which are the major causes of HFMD.
The present invention also provides a method for producing virus like particles of an enterovirus in a mammalian cell system, comprising:
Transfection can be performed by any known method and can result in either transient or stable transfection. Stable transfection can be conducted to establish a cell line producing VLPs of interest.
In some embodiments, the recombinant adenoviral vector for transfecting mammalian cells is replication competent or deficient.
In some embodiments, the mammalian cells to be transfected by the recombinant adenoviral vector are complementing cells that can complement for a deficiency of the adenoviral genome of the replication deficient adenoviral vector as used. Typical examples of the complementing cells are 293 cells or other cells described in for example U.S. Pat. Nos. 6,677,156, 6,913,927 or US 20030017595.
The VLPs as produced in the mammalian cell system can be collected and formulated with a suitable carrier to form a vaccine composition against enterovirus infections. The VLPs thus prepared according to the present invention can be valuable as a vaccine due to glycosylation status similar to that in human.
The present invention is further illustrated by the following examples, which are provided for the purpose of demonstration rather than limitation. Those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
In this study, we have designed and genetically engineered a recombinant adenovirus vector, Ad-EVVLP with the EV71 P1 and 3CD genes inserted into the E1/E3-deleted adenoviral genome. Ad-EVVLP were produced in HEK-293A cells. In addition to Ad-EVVLP particles, virus-like particles (VLPs) formed from the physical association of EV71 capsid proteins, VP0, VP1, and VP3 expressed from P1 gene products. They were digested by 3CD protease and confirmed to be produced by Ad-EVVLP-producing cells, as determined using transmission electron microscopy and western blotting. Mouse immunogenicity studies showed that Ad-EVVLP-immunized antisera neutralized the EV71 B4 and C2 genotypes. Activation of VLP-specific CD4+ and CD8+/IFN-γ T cells associated with Th1/Th2-balanced IFN-γ, IL-17, IL-4, and IL-13 was induced; in contrast, FI-EV71 induced only Th2-mediated neutralizing antibody against EV71 and low VLP-specific CD4+ and CD8+ T cell responses. The antiviral immunity against EV71 was clearly demonstrated in mice vaccinated with Ad-EVVLP in a hSCARB2 transgenic (hSCARB2-Tg) mouse challenge model. Ad-EVVLP-vaccinated mice were 100% protected and demonstrated reduced viral load in both the CNS and muscle tissues. Ad-EVVLP successfully induced anti-CVA16 immunities. Although antisera had no neutralizing activity against CVA16, the 3C-specific CD4+ and CD8+/IFN-γ T cells were identified, which could mediate protection against CVA16 challenge. FI-EV71 did not induce 3C-mediated immunity and had no efficacy against the CVA16 challenge. These results demonstrate that Ad-EVVLP can enhance neutralizing antibody and protective cellular immune responses to prevent EV71 infection and cellular immune responses against CV infection. Ad-EVVLP meets a medical need as a universal HFMD vaccine against both EV71 and CV infections.
1. Materials and Methods
1.1 Ethics Statement
All animal experiments were conducted in accordance with the guidelines of the Laboratory Animal Center of the National Health Research Institutes (NHRI), Taiwan Animal use protocols were reviewed and approved by the NHRI Institutional Animal Care and Use Committee (Approval Protocol No. NHRI-IACUC-100125-A). In EV71 challenge experiments, survival rate was used as an endpoint to assess the protective efficacy of the anti-EV71 treatment. Survival rate used as an index of pathogenesis of EV71 infection has been reported by numerous studies in experimental animal models [16, 19, 21, 22]. After investigation, tested animals were euthanized by 100% CO2 inhalation for 5 min followed by cervical dislocation to minimize suffering. To perform virus challenge, mice were placed in an anesthetic inhalator chamber containing isoflurane (initial phase: 5%; maintenance phase: 1.5%-2.5%) for 1 min before s.c. or i.p. EV71 immunization.
1.2 Cells, Viruses, Compounds, and Antibodies
African green monkey kidney (Vero) (ATCC No. CCL-81) and human rhabdomyosarcoma (RD) (ATCC No. CCL-136) cells were provided by the Taiwan Centers of Disease Control (Taiwan CDC); the original cell lines were obtained from the American Type Culture Collection (ATCC), United States. Vero cells were cultured in a VP-SFM medium (Gibco-Invitrogen, CA, USA) supplemented with 4 mM L-glutamine (Gibco-Invitrogen, CA, USA). The RD cell line was cultured in DMEM medium containing 10% fetal bovine serum (Gibco-Invitrogen, CA, USA). Cells were maintained in a 37° C. incubator equilibrated with 5% CO2. Clinically isolated strains of EV71, E59 (B4) (GenBank: GQ150746.1), Neu (pinf7-54A) strain (C2) (GeneBank DQ060149), Tainan/5746/98 (C2) (GenBank: AF304457.1), and one strain of CVA16, 5079 (GenBank: AF177911.1) were obtained from Dr. Jen-Ren Wang, National Cheng-Kung University, Tainan, Taiwan, and were propagated in Vero cells based on the microcarrier cell culture bioprocess [23,24]. Human adenivirus 5 (Ad5; ATCC No. VR-1516™) was purchased from ATCC and propagated in 293A cells. Virus stocks were stored at −80° C. Virus stock titers were tested in a standard plaque-forming assay [25], and the number of plaque-forming units (pfu) was calculated.
Monoclonal antibody, Mab979 recognized VP0/VP2 capsid protein of EV71 [26] was purchased from Millipore, Inc., MA, USA. A VP1-specific monoclonal antibody E1 produced in house had been described [26]. Antibodies specific to human β-actin (Cat. No. A5441) was purchased from Sigma-Aldrich MO, USA. Horse radish peroxidase (HRP)-conjugated donkey anti-mouse antibody (Cat. No. 715-036-150) or HRP-conjugated rabbit anti-goat antibody (Cat. No. 305-035-003) were purchased from Jackson Immunoresearch, Inc., PA, USA.
1.3. Construction and Production of Ad-EVVLPI and Ad-EVVLPI
The P1 and 3CD genes of the EV71 Neu (pinf7-54A) strain were amplified by PCR and individually inserted into the shuttle vector pENTR4 (Invitrogen). The nucleotide element of the elongation factor-1α (EF-1α) promoter was inserted into the 3′ end of the P1 gene and the 5′ end of the 3CD insert to generate the pENTR4-P1/EF-1α/3CD construct. The 3CD gene alone was inserted into pENTR4 to generate the pENTR4-3CD construct. The pENTR4-P1/EF-1α/3CD and pENTR4-3CD constructs were enzymatically recombined into the ΔE1/ΔE3 (replication-incompetent) Ad5 vector pAd/CMV/V5-DEST [27] to form recombinant pAd-EVVLP and pAd-3CD, respectively. pAd DNA was transfected into the 293A packaging cell line to produce the recombinant adenoviruses designated Ad-EVVLP and Ad-3CD. Ad-LacZ carrying a luciferase reporter gene as a vector control was obtained from Invitrogen. The recombinant viruses were purified and concentrated using Vivapure adenoPACK 100RT (Satorius Stedin Biotech). The purified virus titers were determined using a modified standard plaque assay. Various Ad virus dilutions were added to each well of 293A cells plated in a 6-well tissue culture plate. After overlaying the cultures with DMEM containing 0.75% methylcellulose, the cultures were incubated at 37° C. for 10 to 12 days and plaques were counted. The typical yield of adenoviruses was approximately 1×109 pfu/mL.
1.4. Western Blot
Western blotting was performed as described previously [25]. Total cell lysates were prepared by treating 1 to 2×106 cells with 100 μL ice cold lysis buffer (0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 0.5% NP-40, 50 mM TRIS, 150 mM NaCl) plus a protease inhibitor cocktail (Roche, French) and 1 mM PMSF (Sigma-Aldrich, CA, USA). Lysates were centrifuged for 20 min at 10,000 rpm at 4° C. to sediment the cell debris. The protein concentration of the cell lysates or fractions was measured using the Bradford method [28]. Cell lysates containing 10 μg protein were mixed with loading dye and loaded into each well of a 10% SDS-polyacrylamide gel (SDS-PAGE, Amersham Biosciences-GE Healthcare, USA) and subjected to electrophoresis in 1× Tris-glycine SDS-running buffer. The resolved proteins were transferred onto nitrocellulose membrane (Hybond-ECL, Amersham Biosciences-GE Healthcare, USA). Membranes were soaked in 5% skim milk in 1×PBS for 30 min at room temperature, then washed 3 times with 1×PBS plus 0.05% Tween 20 (PBS-T). The membrane was incubated with rat anti-3C (1:1000), MAB979 (1:5000), or anti-VP1 antibody (1:1000) for 14 to 16 h at 4° C. and subsequently washed with PBS-T followed by incubation with HRP conjugated anti-rat or donkey anti-mouse (for MAB979) antibodies. After 1 h incubation, the membrane was washed 5 times with PBS-T, and then Super Signal West Pico chemiluminescent substrate (Pierce, Ill., USA) was layered onto the membrane, and it was exposed to X-ray film (Kodak, N.Y., USA). When necessary, the membranes were stripped using Restore buffer (Pierce, Ill., USA) and blotted with another antibody.
1.5 Flow Cytometry
Splenocytes were harvested from BALB/c mice and labeled with 5-(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE) (Cat. No. C34554, Molecular Probes). They were restimulated in vitro with 107 pfu/mL UV-inactivated EV71 5746 or 1.4 μg/mL purified recombinant E59 3C proteins expressed by E. Coli. (provided by Dr. Pete Chong, a coauthor of this study) for 5 days. Proliferation of splenocytic CD4+ T cells was analyzed by flow cytometry (BD FACSCalibur) using PE-Cy5-labeled anti-CD4 antibodies. The population of no fluorescence signal-shifting in CFSE-prestained CD4+ T cells without antigen stimulation was set to 0%, and the population of negatively shifted CD4+ T cells (proliferating cells) after antigen stimulation was quantified. The mean percentage corresponding to the individually proliferating CD4+ T cells in each group was calculated. To detect the population of CD8+IFN-γ+ T cells, splenocytes were cocultured with the EV71 antigen for 2 days and then with brefeldin A (Cat. No. 00-4506-51, eBioscience) for 3 h before harvesting. Stimulated splenocytes were stained with PE-Cy5-labeled anti-CD8 antibody for 30 min, followed by subsequent fixation and permeabilization. A portion of these cells was further stained with PE-conjugated anti-IFN-γ+ antibody (BD Bioscience) for 30 min to detect intracellular IFN-γ. After washing, the samples were analyzed by flow cytometry.
1.6 PCR and Real Time RT-PCR
pAd-EVVLP plasmid DNA was used as a template to detect the P1, 3CD, and EF-1α promoter regions within pAd-EVVLP by PCR using the respective primer pairs. The PCR conditions were as follows: 95° C. for 3 min; 35 cycles at 95° C. for 1 min, 60° C. for 1 min, and 72° C. for 3 min; and a final incubation at 72° C. for 2 min.
Total RNA was purified from tissues using TRIZOL reagent (Invitrogen, CA, USA) following the manufacturer's instructions and was subjected to real time RT-PCR. Total RNA was converted into cDNA using random primers (Genomics BioSci&Tech, Taiwan) and reverse transcriptase (Bionovas, Toronto, Canada). The synthesized cDNA was subjected to quantitative PCR analysis (LightCycler 480 SYBR Green Real-Time PCR system) using primer pairs specific to the VP1 region of EV71 P1 RNA. Human β-actin gene expression was used as an internal control. The PCR conditions were as follows: 95° C. for 3 min; 40 cycles at 95° C. for 10 s, 65° C. for 20 s, and 72° C. for 2 s; and a final incubation at 72° C. for 2 min. The number of cycles required for amplification of transcripts was obtained. The relative expression of EV71 P1 RNA was calculated as follows: the individual Ct obtained from the experimental group or control group was subtracted by its respective Ct (β-actin) to gain normalized Ct, and then 2Normalized Ct (VP1 of P1 RNA from the sample without viral infection) was divided by 2Normalized Ct (VP1 of P1 RNA from the sample with viral infection). The forward and reverse primers, [5_-ACGCGCAAATGCGTAGAAAGGT-3_-forward (SEQ ID NO: 7) and 5_-TTAGTGGCAGTTTGCCATGCGA-3_-reverse (SEQ ID NO: 8)], were used to amplify and detect VP1 RNA. human β-actin mRNA was amplified using the primer pairs 5_-ACCAACTGGGACGACATGGAGAAA-3_-forward (SEQ ID NO: 9) and 5_-TAGCACAGCCTGGATAGCAACGTA-3_-reverse (SEQ ID NO: 10). Primer pairs targeting the P1, 3CD, and EF-1α promoter regions of Ad-EVVLP are as follows: P1: 5_-ATCG GAATTCATGGGCTCACAGGTGTCCAC-3_-forward (SEQ ID NO: 11) and 5_-CTTGTCGACTTAGAGAG TGGTAATTGCTG-3— (SEQ ID NO: 12)-reverse, 3CD: 5_-ATCGGAATTCATGGGGCCGAGCTTGGAC-3_-forward (SEQ ID NO: 13) and 5_-ATCGCTCGAGAAACAATTCGAGCC-3_-reverse (SEQ ID NO: 14), EF-1Δ promoter: 5_-ATCGACGCGTGTGAGGCTCCGGTGCCC-3_-forward (SEQ ID NO: 15) and 5_-ATCGCCCGGGGTTTTCACGACACCTG-3_-reverse (SEQ ID NO: 16). All primer sets were commercially synthesized by Genomics BioSci&Tech, Taiwan.
1.7 Density Gradient Purification of EV71 VLP and Ad
HEK-293A cells (1×107) were seeded in a 10-well plate 1 day prior to Ad-EVVLP infection with MOI=1. After 24 h of infection, the cells were harvested and lysed in 1% NP-40 lysis buffer (50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, and 1% NP-40) on ice for 30 min and centrifuged at 1000×g for 10 min to remove the cell debris. The supernatants were harvested and concentrated by ultracentrifugation at 100,000×g for 1 h at 4° C. and then dissolved in 30 μL PBS. The samples were loaded into self-generated iodixanol gradients, which were prepared by mixing 0.6 mL solution S (0.25 M sucrose, 15 mL EDTA, 30 mM Tris/HCl, pH 8.0) and 0.42 mL 60% (w/v) iodixanol (Cat. No. 1114542, Optiprep; Axis Shield, UK) to form a homogenous solution. Gradients were generated through centrifugation at 162,000×g for 24 h at 4° C. The various fractions were manually harvested from the top (named Fraction No. 1), 0.1 mL per fraction, and 10 fractions were serially collected for each sample. These fractions were subjected to Western blot using Mab979 antibodies or transmission electron microscopy.
1.8 Transmission Electron Microscopy
HEK-293A cells were harvested 24 h after Ad-EVVLP infection, and cell pellets were frozen and thawed twice at −80° C. for 30 min and 37° C. for 15 min. Lysates were centrifuged at 3000 rpm for 15 min at room temperature, and supernatants were harvested and subjected to examine adenovirus using a JEOL JEM-1400 transmission electron microscope (TEM). The lysate was fractionated through density gradient centrifugation, and fractions were concentrated through ultracentrifugation at 100,000×g for 1 h and resuspended in 200 μL PBS. The fractions were then cleaned by centrifugation in a 100 KDa-cut-off spin-XR UF 20 column (Corning). Samples were treated with uranyl acetate and inspected by TEM.
1.9 ELISA
To detect anti-EV71, anti-Ad, or anti-3C antibodies in sera, 96-well plates were coated with 100 μL per well of heat-inactivated (56° C. for 1 h) 103 pfu EV71 5746 (C2 genotype) or E59 (B4 genotype) strains, 200 pfu purified Ad5, or 700 ng recombinant 3C protein in carbonate coating buffer. Serum samples collected from immunized mice were inactivated at 56° C. for 30 min. Two-fold serial dilutions of the sera were performed beginning from an 8-fold initial dilution. The diluted sera were added to the wells and incubated at room temperature for 2 h. After washing with PBS-T, HRP-conjugated donkey anti-mouse IgG antibodies were added to the wells for 45 min. The reaction was developed by incubation with 100 μL TMB substrate (3, 3′,5,5′-etramethyllbenzidine) for 20 min in the dark and terminated by adding 50 μL 2 N H2SO4. The optical density at 450 nm was determined using a microplate absorbance reader (SPECTRA, MAX2, M2). To detect cytokines secreted by splenocytes, the supernatants from 2-day cultures of splenocytes restimulated with 107 pfu/mL UV-inactivated EV71 5746 were analyzed using a calorimetric sandwich IFN-γ, IL-4, IL-13, and IL17A ELISA kit (Cat. No. 887314, 88-7044, 88-7137, and 88-7371, respectively, eBioscience). The assays were conducted according to the manufacturer's instructions, and the optical densities at 450 nm were determined using a microplate absorbance reader.
1.10 Neutralizing Assay
To detect the neutralizing activity as described in our previous study [26], each sample was serially diluted 2-fold in fresh cell culture medium. A total of 100 μL 100 TCID50 virus suspension, E59, 5746, or CVA16 strain was added to each tube containing 100 μL serially diluted serum. After incubation at 4° C. for 18 to 24 h, 100 μL virus serum mixture was added to 96-well plates seeded with rhadomyosarcoma (RD) cells and incubated for 7 days at 37° C.; TCID50 values were measured by counting cytopathic effects (CPE). The 50% neutralization inhibition dose (ID50) was calculated as the reciprocal of the serum dilution compared to normal serum using the Reed-Muench method [29]. A mouse anti-EV71 Mab979 antibody (Chemicon International) was used as an internal positive control.
1.11 Enzyme-linked Immunosorbent Spot Assay
Suspensions containing 5×106 RBC-free splenocytes were prepared from individual mice and seeded in individual wells of 96-well filtration plates (Millipore) pre-coated with capturing monoclonal antibodies for murine IL-4 or IFN-γ (0.5 μg/well) (Cat. No. 16-7041-68 or 16-7313-68, respectively, eBioscience) and blocked with conditioned medium (CM) for 1 h at room temperature. The splenocytes were added to 106 pfu/well UV-inactivated EV71 5746 dissolved in CM (100 μL). Splenocytes incubated with Con A (10 μg/mL) were used as a positive control. Unstimulated splenocytes were used as a negative control. Plates were maintained in a 37° C. incubator equilibrated with 5% CO2 for 48 h. The individual wells of the ELISPOT plates were washed 3 times with PBS-T, and 0.2 μg of the corresponding biotinylated detection monoclonal IL-4- or IFN-γ-specific antibody was added to detect the respective cytokines. The plates were washed after 2 h incubation at room temperature, and 100 μL streptavidin-alkaline phosphatase (1:250 dilution) was added to the individual wells. The plates were incubated at room temperature for 45 min Finally, the plates were washed 4 times with wash buffer, and 100 μL AEC (3-amine-9-ethylcarbazole, Sigma-Aldrich) substrate was added to each well and allowed to react for 30 min at room temperature in the dark. The plates were washed with water, air-dried overnight, and the spots on each well were scored using an immunospot counting reader (Immunospot, Cellular Technology Ltd.). The results were expressed as the number of cytokine-secreting cells per 5×105 splenocytes seeded in the initial culture.
1.12 Ad-EVVLP Vaccination of hSCARB2 Transgenic Mice Challenged with EV71 and CVA16
hSCARB2-Tg mice in a C57BL/6 background generated were previously generated by our group and were maintained by cross-mating hSCARB2-Tg subjects to obtain inbred mice [16]. One-day-old hSCARB2-Tg mice were inoculated s.c. with PBS, 3×107 pfu Ad-LacZ, or 3×106 or 3×107 pfu Ad-EVVLP, or 1 μg FI-EV71 vaccine on Days 1 and 7, and then challenged s.c. with 3×106 pfu EV71 5746 or 5×105 pfu CVA16 on Day 14. The mice were monitored daily for survival for 15 days after the challenge.
1.13 Statistical Analysis
Logrank test was used to analyze the difference in survival rate of drug-treated and non-treated transgenic mice. The unpaired t test with Welch's correction statistic was used to analyze the difference of the tested gene expression between experimental groups. Results are considered statistically significant with a p value of <0.05. The symbols * and ** are used to indicate p values <0.05 and <0.01, respectively.
2. Results
2.1 Ad-EVVLP and VLP Production in HEK-293A Cells
We used the E1- and E3-deleted adenovirus-5 genome to construct the Ad-EVVLP expression vector, which carried full-length P1 and 3CD genes of EV71 (
To demonstrate that the EV71 VLP particles were cogenerated in Ad-producing cells, we purified the virions from the cytosol of Ad-EVVLP transfectant using fractionation through density gradient centrifugation. We fractionated EV71 particles as a control. We characterized each fractionated sample by Western blot analysis using Mab979. The major band was 38 kDa, corresponding to VP0, but there was minor expression of a 28 kDa corresponding to VP2 (intensity ratio of VP0/VP2=4 and 6, respectively), which together make the E-particle of EV71 in Fractions 6 and 7. In contrast, the opposite pattern of VP0/VP2 expression (0.8, 0.9, and 0.8, respectively) corresponding to F-particles was observed in Fractions 8, 9, and 10. However, only VP0 signals were detected in Fractions 6 to 9 of Ad-EVVLP-infected lysate (
We pooled Fractions 7 and 8 of Ad-EVVLP samples and examined them by TEM. TEM analysis revealed some fractured VLPs (f) and cellular impurities in the samples due to sample preparation. Two sizes of complete particles were also present; particles over 100 nm in diameter corresponded to Ad particles (
2.2 EV71 VLP-specific Humoral Responses in Ad-EVVLP-immunized Mice
To examine the immunogenicity of Ad-EVVLP compared to the FI-EV71 vaccine, we intraperitoneally (i.p.), subcutaneously (s.c.), or orally administered adult BALB/c mice with 1×108 pfu of Ad-EVVLP or Ad-LacZ on Days 1 and 14 . Animals in separate groups were s.c. administered 0.1 μg or 1 μg FI-EV71 twice to evaluate the virus-specific immune responses compared with those of recombinant adenoviruses. The results of ELISA assays showed (
2.3 Induction of VLP-specific Cellular Immunities in Ad-EVVLP-immunized Mice
Recent studies on host immune responses against EV71 have suggested that T cell immunity plays a critical role in the protection against EV71 infection and control of the disease [33,34]. Therefore, we investigated whether the VLP-specific CD4+ and CD8+ T cell responses could be elicited in Ad-EVVLP-immunized mice. Seven days post-immunization, we isolated lymphocytes from the spleen, followed by in vitro restimulation with UV-inactivated EV71 (UV-EV71). Lymphocytes from Ad-LacZ-immunized mice produced background IFN-γ levels. In contrast, substantially higher IFN-γ levels were measured in lymphocyte cultures from mice administered Ad-EVVLP (
We measured VLP-specific CD4+ T cell proliferation in vaccine-immunized splenocytes followed by restimulation with UV-EV71 by examining the negative shift of fluorescent signal in 5-(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)-prestained CD4+ T cells using flow cytometry. Compared to little or no shift of signals in the PBS- and Ad-LacZ-immunized groups (3% and 8.4%, respectively), a substantial shift was detected in Ad-EVVLP-immunized group (42%;
2.4 Ad-EVVLP Vaccine Confers Protection Against EV71 Infection in hSCARB2-Tg Mice
We further assessed the efficacy of Ad-EVVLP in protecting against EV71 infection using the hSCARB2-Tg mice model. One-day-old hSCARB2-Tg mice were primed and s.c. boosted with Ad or FI-EV71 vaccine on Days 1 and 7, followed by s.c. challenge of 3×106 pfu EV71 5746 strain 14 days after birth. Mice were monitored daily for survival. As shown in
2.5 3C-specific Immune Responses Generated in Ad-EVVLP-immunized Mice
3C and 3D are proteins conserved between EV71 and CVs (A16, A6, A10, and A4) that share at least 90% homology in their amino acid sequences (Table 2).
We examined whether 3C-specific immunities were induced by Ad-EVVLP vaccination. We collected and assayed serum from mice on Day 7 post-prime-boost s.c. with Ad-EVVLP, Ad-LacZ, or FI-EV71. Serum from Ad-EVVLP-immunized mice elicited activity against 3C protein in a recombinant 3C-protein-coated ELISA capturing assay. Anti-3C binding activity was not detected in serum from Ad-LacZ- or FI-EV71-immunized mice (
We further examined 3C-specific cellular immunity in mice immunized with Ad-EVVLP. We isolated splenocytes on Day 7 after vaccine boost and restimulated them with recombinant 3C protein in vitro and observed of CD4+ and CD8+ T cell activation by flow cytometry (
2.6 Ad-EVVLP Vaccine Confers Protection Against CVA16 Infection in hSCARB2-Tg Mice
In addition to the protection against EV71 infection, we investigated whether Ad-EVVLP or FI-EV71 can facilitate hSCARB2-Tg mice in resisting lethal CVA16 challenge. After Ad-EVVLP immunization, 100% of hSCARB2-Tg mice survived, in contrast to 0% survival of hSCARB2-Tg mice that received PBS or Ad-LacZ after CVA16 challenge (
3. Discussion:
In previous studies, EV71 subunit vaccines including DNA vaccine and recombinant VP1 protein induced an incomplete immune response and showed lower efficacy [19,37]. Oral vaccines, such as those against attenuated Salmonella enterica expressing EV71 VP1, have demonstrated limited efficacy against EV71, elevating the survival rates to only 50% after viral challenge [38]. Transgenic tomatoes [39] and peptide vaccines [40] expressing VP1 have also been developed, but the vaccine efficacy has not been assessed in vivo. A denatured virus particle containing formalin as a vaccine (FI-EV71) was tested in a hSCARB2-Tg mice model [16] and in human clinical trials [32], in which its safety and protective efficacy was demonstrated. A previous study on the development of influenza VLP as a vaccine showed that disrupting the influenza VLP structure abolished humoral immune responses and protective immunity [41]. In addition, the denatured EV71 particle possesses linear epitopes to elicit anti-EV71 antibodies; however, most of them are likely to be nonneutralizing, similar to the case of poliovirus [42]. Loss of the induction of effective neutralizing antibodies may be associated with the loss of antigenic determinants during inactivation, such as denatured EV71 particles by formalin. VLPs expressed in insect cells elicited even lower levels of neutralizing antibody titer, proliferation, and cytokine production in monkeys [35]. This may be due to differential post-translational modification of VLP proteins in nonhuman cells to induce differential immune responses. In contrast, intact VLPs produced from host cells preserve conformation-dependent epitopes, which might enable direct interaction of VLPs with B-cell receptors, activating B cells and antigen internalization through antigen-presenting cells [43]. This triggers potent antibody responses [44] and cross switching through cooperation with stimulated CD4+ T cells [45]. Furthermore, recent studies have shown that neutralizing antibodies, specifically those against the EV71 capsid proteins, cannot cross-protect against CV infection [36,46], indicating that the vaccines currently being developed protect against only EV71-induced HFMD.
In this study, we evaluated the potential of adenovirus-expressing EV71 VLP as a vaccine candidate against EV71 and CVA16 infections through comparison with the efficacies and immune responses elicited by Ad-EVVLP and the classical preparation of formalin-inactivated EV71 vaccine Immunization with Ad-LacZ elicited no EV71-specific antibody titers and low levels of T cell responses, compared to Ad-EVVLP and FI-EV71 vaccines, which strongly induced the anti-EV71 antibody titer (
Previous studies have shown that preexisting anti-adenovirus antibodies do not affect subsequent generations of humoral responses to an antigen expressed through a mucosally administered recombinant adenovirus vector [47-49]. However, Ad-EVVLP oral immunization induced a decreased immune response compared to the mice receiving systemic Ad-EVVLP immunization (s.c. or i.p.;
In addition to humoral responses, VLPs from other viruses have been reported to induce dendritic cell (DC) maturation and cytokine secretion [16,17], and can stimulate CD4+ [18] and CD8+ T cells [19,20]. Ad is a strong DC activator, which enzymatically processes and presents antigenic peptides associated with MHC class I and II molecules on the surface, and subsequently coordinates and stimulates T helper and cytotoxic T-cell responses [50]. Ad-EVVLP immunization induced capsid protein-specific cellular immune responses, which was confirmed by the EV71 VLP induction of CD4+ and CD8+ T cell activation (
CD4+ and CD8+ T cell-mediated cellular responses corresponding to the recombinant 3C protein in Ad-EVVLP- but not FI-EV71 vaccine-immunized mice was also observed (
In conclusion, VLP expression in host cells through the replication of defective adenovirus mimicking the natural structure of EV71 particles induced antibodies against VLP and 3C proteins and cellular immunities specific to VLP and 3C proteins. Because the 3C protein is highly conserved between EV71 and CVA (Table 2), we demonstrated that Ad-EVVLP acts as a multivalent vaccine to suppress EV71 and CVA16-induced disease. We achieved several breakthroughs in the development of a medically necessary enterovirus vaccine. First, instead of the subunit EV71 vaccine, inactivated EV71 vaccine, or protein-typed VLPs that protect against only EV71-induced HFMD, Ad-EVVLP prevents EV71- and CVA-induced HFMD. Second, induction of 3C-specific cellular immunity might sufficiently protect against CVA infection.
Sequence Information
This application is a national stage filing under 35 U.S.C. § 371 of international PCT application PCT/US2015/022738, filed Mar. 26, 2015, which claims the benefit of U.S. Provisional Patent Application No. 61/985,803, filed Apr. 29, 2014 under 35 U.S.C. § 119(e), the content of each of which is herein incorporated by reference in its entirety.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2015/022738 | 3/26/2015 | WO | 00 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2015/167710 | 11/5/2015 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 20030148511 | Ashton-Rickardt | Aug 2003 | A1 |
| Number | Date | Country |
|---|---|---|
| WO2013142809 | Sep 2013 | WO |
| Entry |
|---|
| UniProt database entry A3KBJ1, A3KBJ1_9ENTO, 2007: pdf p. 1. |
| UniProt number: A3KBJ1. Apr. 3, 2007. |
| Genbank Accession DQ060149. NCBI. Jun. 11, 2005. Wu et al. |
| Number | Date | Country | |
|---|---|---|---|
| 20170056491 A1 | Mar 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61985803 | Apr 2014 | US |
